2025 United Kingdom Cell And Gene Therapy Manufacturing Services Market Revenue Opportunities Report
Description
The 2025 United Kingdom Cell And Gene Therapy Manufacturing Services Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cell and Gene Therapy Manufacturing Services Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Cell and Gene Therapy Manufacturing Services Market in the United Kingdom include Autolus Therapeutics, Oxford Biomedica plc, Cell and Gene Therapy Catapult, and Orchard Therapeutics. Autolus, based in London, is a clinical-stage CAR-T cell therapy company with FDA approval for its lead product and operates dedicated manufacturing facilities such as The Nucleus for commercial CAR-T products, driving personalized oncology treatments. Oxford Biomedica plc is a key UK player known for their advanced gene and cell therapy manufacturing capabilities, partnering globally to provide process development and GMP manufacturing. The Cell and Gene Therapy Catapult is a government-supported innovation center fostering manufacturing scale-up, infrastructure growth, and industry collaborations to accelerate ATMP development in the UK. Orchard Therapeutics, headquartered in London, focuses on gene therapies targeting hematopoietic stem cells with global commercialization experience, contributing significantly to the UK's leadership in gene therapy.
These companies benefit from the UK’s expanding manufacturing infrastructure, including 32 MHRA-licensed GMP facilities, increased cleanroom footprint, and government-backed investments totaling £520 million announced for life sciences manufacturing between 2025 and 2030. The sector employs over 7,000 specialists and drives significant innovation in oncology, neurological, and autoimmune disease therapies. Strategic partnerships with global biopharmaceutical firms and continuous pipeline advancements position these companies at the forefront of cell and gene therapy manufacturing services within the UK market.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cell and Gene Therapy Manufacturing Services Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Cell and Gene Therapy Manufacturing Services Market in the United Kingdom include Autolus Therapeutics, Oxford Biomedica plc, Cell and Gene Therapy Catapult, and Orchard Therapeutics. Autolus, based in London, is a clinical-stage CAR-T cell therapy company with FDA approval for its lead product and operates dedicated manufacturing facilities such as The Nucleus for commercial CAR-T products, driving personalized oncology treatments. Oxford Biomedica plc is a key UK player known for their advanced gene and cell therapy manufacturing capabilities, partnering globally to provide process development and GMP manufacturing. The Cell and Gene Therapy Catapult is a government-supported innovation center fostering manufacturing scale-up, infrastructure growth, and industry collaborations to accelerate ATMP development in the UK. Orchard Therapeutics, headquartered in London, focuses on gene therapies targeting hematopoietic stem cells with global commercialization experience, contributing significantly to the UK's leadership in gene therapy.
These companies benefit from the UK’s expanding manufacturing infrastructure, including 32 MHRA-licensed GMP facilities, increased cleanroom footprint, and government-backed investments totaling £520 million announced for life sciences manufacturing between 2025 and 2030. The sector employs over 7,000 specialists and drives significant innovation in oncology, neurological, and autoimmune disease therapies. Strategic partnerships with global biopharmaceutical firms and continuous pipeline advancements position these companies at the forefront of cell and gene therapy manufacturing services within the UK market.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
